6. IPF Drug in Phase 2 Study Reduced Lung Fibrosis, Improved Function in 35% of Patients
FibroGen, Inc., recently disclosed potentially groundbreaking results from a Phase 2 clinical trial evaluating the efficacy of the company’s investigational drug FG-3019 in the treatment of idiopathic pulmonary fibrosis (IPF). Data indicated that the monoclonal antibody agent was able to reduce lung fibrosis in a portion of the IPF patients enrolled, to improve overall lung function.
Read more about it: http://bit.ly/1QXvDWm